新华财经上海9月10日电 (谷青竹) 9月10日,司美格鲁肽注射液(商品名:诺和盈)的代谢相关脂肪性肝炎(MASH)适应症上市申请获得中国国家药品监督管理局批准,成为国内首个获批用于治疗MASH的GLP-1类药物。 肝脏作为人体代谢中心,犹如身体的“回收处理站”,其功能障碍会导致各类代谢产物和毒素无法被清理和排出,从而引发全身性的“连锁健康危机”。“脂肪肝早期通常‘无声无息’,不会带来明显的身体...
Source Link新华财经上海9月10日电 (谷青竹) 9月10日,司美格鲁肽注射液(商品名:诺和盈)的代谢相关脂肪性肝炎(MASH)适应症上市申请获得中国国家药品监督管理局批准,成为国内首个获批用于治疗MASH的GLP-1类药物。 肝脏作为人体代谢中心,犹如身体的“回收处理站”,其功能障碍会导致各类代谢产物和毒素无法被清理和排出,从而引发全身性的“连锁健康危机”。“脂肪肝早期通常‘无声无息’,不会带来明显的身体...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.